GLP-1 drugs and PCOS: what the science says vs. TikTok

What's this video probably claiming?

Based on the caption, hashtags, and sponsored nature of this post, @catreaamcknight is almost certainly showing a before-and-after body transformation and attributing it to GLP-1 receptor agonist therapy accessed through Mochi Health, a telehealth platform that prescribes weight-loss medications. The PCOS hashtag suggests she may be framing GLP-1 treatment as particularly helpful for people with polycystic ovary syndrome, a condition strongly linked to insulin resistance and weight gain. The $40 affiliate discount and #mochipartner tag confirm this is paid content. Creators in this category typically claim the drug made weight loss finally possible after years of struggling, that PCOS makes standard diet advice ineffective, and that telehealth access removed barriers to treatment. Some go further and imply the medication corrected hormonal symptoms beyond weight. Without a transcript we can't confirm the exact claims, but the framing is consistent across hundreds of similar sponsored posts in this category.

What does the science actually show?

GLP-1 receptor agonists do have meaningful data in both obesity and PCOS contexts, but the numbers deserve honesty. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4 mg weekly produced roughly 14.9% mean body weight loss over 68 weeks in adults with obesity, compared to 2.4% with placebo. That's real. For PCOS specifically, a 2023 randomized controlled trial by Jensterle et al. in the Journal of Clinical Endocrinology and Metabolism found that semaglutide outperformed metformin on weight reduction and showed modest improvements in androgen levels and menstrual regularity in women with PCOS. A 2022 review by Tay et al. in Obesity Reviews confirmed GLP-1 agonists reduce insulin resistance markers in PCOS populations. The mechanism makes biological sense. But average results in trials involve supervised titration, dietary support, and follow-up. A TikTok transformation photo represents one person's outcome, not a population average.

Where does the social media noise diverge from clinical reality?

Several gaps are worth naming directly. First, before-and-after photos tell you nothing about timeline, lifestyle changes, or whether the weight loss was maintained. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that roughly two-thirds of lost weight returned within a year of stopping semaglutide, a fact that almost never appears in sponsored content. Second, the PCOS framing can mislead. GLP-1 drugs are not FDA-approved specifically for PCOS. Using them off-label for hormonal symptom management is biologically plausible but not the same as established treatment. Third, Mochi Health and similar platforms may prescribe compounded semaglutide, which is not the same formulation as FDA-approved Wegovy or Ozempic. The FDA has explicitly warned that compounded versions have not been proven safe or effective equivalents. Creators rarely disclose this distinction. Finally, side effects including nausea, vomiting, and in rare cases pancreatitis, are consistently underrepresented in transformation content.

What should you actually know?

If you have PCOS and are considering a GLP-1 agonist, the conversation should start with a qualified clinician who reviews your full metabolic picture, not a discount code in a bio. GLP-1 drugs can be appropriate for PCOS patients with concurrent obesity or insulin resistance, but they are not a universal PCOS treatment. Ask your provider whether they are prescribing an FDA-approved branded product or a compounded version, and ask what the plan is if you want to stop. Weight regain after discontinuation is a clinical reality documented in multiple trials, and any prescriber who doesn't discuss that upfront is doing you a disservice. Sponsored telehealth content is advertising. It may feature real outcomes, but it is selected precisely because those outcomes are compelling, not because they are representative. The actual median result for any given patient is quieter than a TikTok transformation video.